PT3347002T - Tratamento de doença de alzheimer numa população particular de pacientes - Google Patents

Tratamento de doença de alzheimer numa população particular de pacientes

Info

Publication number
PT3347002T
PT3347002T PT168451813T PT16845181T PT3347002T PT 3347002 T PT3347002 T PT 3347002T PT 168451813 T PT168451813 T PT 168451813T PT 16845181 T PT16845181 T PT 16845181T PT 3347002 T PT3347002 T PT 3347002T
Authority
PT
Portugal
Prior art keywords
methods
particular patient
patient population
neurodegenerative disorders
treating neurodegenerative
Prior art date
Application number
PT168451813T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3347002(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of PT3347002T publication Critical patent/PT3347002T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT168451813T 2015-09-10 2016-09-09 Tratamento de doença de alzheimer numa população particular de pacientes PT3347002T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
PT3347002T true PT3347002T (pt) 2023-07-27

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168451813T PT3347002T (pt) 2015-09-10 2016-09-09 Tratamento de doença de alzheimer numa população particular de pacientes

Country Status (21)

Country Link
US (3) US11191742B2 (https=)
EP (2) EP3347002B1 (https=)
JP (4) JP6789579B2 (https=)
KR (2) KR102547164B1 (https=)
CN (3) CN116712422A (https=)
AU (1) AU2016319107B2 (https=)
CA (1) CA2997376C (https=)
DK (1) DK3347002T3 (https=)
ES (1) ES2952727T3 (https=)
FI (1) FI3347002T3 (https=)
HR (1) HRP20230809T1 (https=)
HU (1) HUE062511T2 (https=)
LT (1) LT3347002T (https=)
MD (1) MD3347002T2 (https=)
MX (2) MX392677B (https=)
PL (1) PL3347002T3 (https=)
PT (1) PT3347002T (https=)
RS (1) RS64481B1 (https=)
SI (1) SI3347002T1 (https=)
SM (1) SMT202300250T1 (https=)
WO (1) WO2017044840A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
IL316611A (en) * 2018-08-01 2024-12-01 Alzheon Inc Sulfopropanoic acid derivatives for treating neurodegenerative disorders
JP7573512B2 (ja) * 2018-08-01 2024-10-25 アルツェオン・インコーポレーテッド 神経変性障害を治療するための方法
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
RU2724190C2 (ru) * 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Also Published As

Publication number Publication date
MX2022003128A (es) 2022-08-02
EP4275750A3 (en) 2024-01-17
HUE062511T2 (hu) 2023-11-28
SI3347002T1 (sl) 2023-12-29
JP7128536B2 (ja) 2022-08-31
US11191742B2 (en) 2021-12-07
JP6789579B2 (ja) 2020-11-25
EP3347002B1 (en) 2023-06-07
RS64481B1 (sr) 2023-09-29
KR102412997B1 (ko) 2022-06-23
HK1257874A1 (en) 2019-11-01
CN116712423A (zh) 2023-09-08
US20230414541A1 (en) 2023-12-28
MD3347002T2 (ro) 2023-10-31
MX392677B (es) 2025-03-24
JP2018526407A (ja) 2018-09-13
US20220096406A1 (en) 2022-03-31
SMT202300250T1 (it) 2023-09-06
ES2952727T3 (es) 2023-11-03
MX2018003023A (es) 2018-06-06
KR102547164B1 (ko) 2023-06-22
CA2997376C (en) 2024-05-14
AU2016319107B2 (en) 2021-02-25
CA2997376A1 (en) 2017-03-16
AU2016319107A1 (en) 2018-03-22
CN116712422A (zh) 2023-09-08
FI3347002T3 (fi) 2023-08-10
KR20180051561A (ko) 2018-05-16
EP4275750A2 (en) 2023-11-15
EP3347002A1 (en) 2018-07-18
CN108289870A (zh) 2018-07-17
PL3347002T3 (pl) 2023-11-13
KR20220042480A (ko) 2022-04-05
JP2022145949A (ja) 2022-10-04
EP3347002A4 (en) 2019-04-24
WO2017044840A1 (en) 2017-03-16
LT3347002T (lt) 2023-09-11
DK3347002T3 (da) 2023-08-14
JP2020200352A (ja) 2020-12-17
HRP20230809T1 (hr) 2023-10-27
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL264641A (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
PT3347002T (pt) Tratamento de doença de alzheimer numa população particular de pacientes
IL248732A0 (en) Compounds for the treatment of ophthalmological diseases and disorders
IL255423A0 (en) Methods for treating neurodegenerative disease
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL249602A0 (en) Methods and devices for the treatment of posterior ocular disorders
SG11201703193XA (en) Treatment for depression and depressive disorders
IL269106A (en) Methods for the treatment of neurodegenerative diseases
GB201516905D0 (en) Treatment of Neurodegenerative diseases
SG11201704829QA (en) Methods and compositions for treating brain diseases
ZA201800831B (en) Compositions and methods for treating and preventing neurodegenerative disorders
IL253847A0 (en) Methods of treating diseases
IL254155A0 (en) pain treatment
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
GB201408387D0 (en) Treatment of respiratory disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201604658D0 (en) Treatment for pain
IL260046A (en) Preparations containing benzophenone polyhydroxyls and methods for treating neurodegenerative disorders
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
GB201512139D0 (en) Methods of treatment
GB201413532D0 (en) Combination therapy for treating hearing disorders
GB201602011D0 (en) Treating skin disorders
GB201602784D0 (en) New treatment of CFTR-related disorders